Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

, BIIB

Biogen

$305.59

-0.4 (-0.13%)

07:22
10/10/16
10/10
07:22
10/10/16
07:22

Ionis drug likely to be approved rapidly, says Wells Fargo

After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.

IONS

Ionis Pharmaceuticals

BIIB

Biogen

$305.59

-0.4 (-0.13%)

  • 10

    Oct

  • 26

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals

10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
BIIB Biogen
$305.59

-0.4 (-0.13%)

09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

TODAY'S FREE FLY STORIES

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/19/17
02/19
04:55
02/19/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

QUNR

Qunar

$30.88

-0.14 (-0.45%)

15:28
02/18/17
02/18
15:28
02/18/17
15:28
Conference/Events
Qunar to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

REG

Regency Centers

$69.75

0.23 (0.33%)

, EQY

Equity One

$31.29

0.16 (0.51%)

15:21
02/18/17
02/18
15:21
02/18/17
15:21
Conference/Events
Equity One to host special shareholder meeting »

Special Shareholder…

REG

Regency Centers

$69.75

0.23 (0.33%)

EQY

Equity One

$31.29

0.16 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

EQY

Equity One

$31.29

0.16 (0.51%)

, REG

Regency Centers

$69.75

0.23 (0.33%)

15:18
02/18/17
02/18
15:18
02/18/17
15:18
Conference/Events
Regency Centers to host special shareholder meeting »

Special Shareholder…

EQY

Equity One

$31.29

0.16 (0.51%)

REG

Regency Centers

$69.75

0.23 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$7.05

0.03 (0.43%)

, ELNK

EarthLink

$5.63

-0.01 (-0.18%)

15:12
02/18/17
02/18
15:12
02/18/17
15:12
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.05

0.03 (0.43%)

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

, WIN

Windstream

$7.05

0.03 (0.43%)

15:09
02/18/17
02/18
15:09
02/18/17
15:09
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.63

-0.01 (-0.18%)

WIN

Windstream

$7.05

0.03 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

HNR

Harvest Natural

14:50
02/18/17
02/18
14:50
02/18/17
14:50
Conference/Events
Harvest Natural to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

, CLC

Clarcor

14:30
02/18/17
02/18
14:30
02/18/17
14:30
Conference/Events
Clarcor to host special shareholder meeting »

Special Shareholder…

PH

Parker-Hannifin

$153.89

-0.52 (-0.34%)

CLC

Clarcor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AZN

AstraZeneca

$29.16

0.4 (1.39%)

, BAYRY

Bayer

$113.29

0.05 (0.04%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2017 Genitourinary…

AZN

AstraZeneca

$29.16

0.4 (1.39%)

BAYRY

Bayer

$113.29

0.05 (0.04%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

ESALY

Eisai

$54.40

0.205 (0.38%)

EXEL

Exelixis

$23.12

0.47 (2.08%)

GHDX

Genomic Health

$29.11

0.61 (2.14%)

MRK

Merck

$65.39

0.13 (0.20%)

MYGN

Myriad Genetics

$18.62

1.35 (7.82%)

NVS

Novartis

$77.20

0.47 (0.61%)

OPK

OPKO Health

$8.81

0.06 (0.69%)

PFE

Pfizer

PGNX

Progenics

$10.62

0.08 (0.76%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

  • 08

    Mar

  • 09

    Mar

  • 15

    Mar

  • 17

    Mar

  • 23

    Mar

  • 29

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

  • 26

    Jun

MDT

Medtronic

$78.88

0.89 (1.14%)

, NVO

Novo Nordisk

$35.46

0.02 (0.06%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Kenes International Organizers to hold a conference »

10th International…

MDT

Medtronic

$78.88

0.89 (1.14%)

NVO

Novo Nordisk

$35.46

0.02 (0.06%)

RHHBY

Roche

$30.53

0.02 (0.07%)

ABT

Abbott

$44.69

0.49 (1.11%)

SNY

Sanofi

$43.16

-0.38 (-0.87%)

LLY

Eli Lilly

$80.39

0.35 (0.44%)

DXCM

Dexcom

$81.89

0.5 (0.61%)

JNJ

Johnson & Johnson

$118.86

0.78 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 24

    Feb

  • 24

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 29

    Mar

  • 19

    Apr

  • 26

    Jun

AXP

American Express

$79.71

0.2 (0.25%)

, MAT

Mattel

$26.10

0.43 (1.68%)

04:55
02/18/17
02/18
04:55
02/18/17
04:55
Conference/Events
Toy Industry Association to hold fair »

International Toy Fair…

AXP

American Express

$79.71

0.2 (0.25%)

MAT

Mattel

$26.10

0.43 (1.68%)

HAS

Hasbro

$98.50

0.86 (0.88%)

COST

Costco

$175.86

0.11 (0.06%)

AMZN

Amazon.com

$845.07

0.93 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

PKY

Parkway

$21.58

0.08 (0.37%)

18:20
02/17/17
02/17
18:20
02/17/17
18:20
Hot Stocks
Parkway to sell 49% interest in Houston Greenway portfolio for $512.1M »

Parkway announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 01

    Mar

VIA

Viacom

$47.00

-0.2 (-0.42%)

, VIAB

Viacom

$43.99

-0.17 (-0.38%)

18:15
02/17/17
02/17
18:15
02/17/17
18:15
Periodicals
Paramount CEO Brad Grey to leave studio as early as next week, Reuters says »

Brad Grey, chairman and…

VIA

Viacom

$47.00

-0.2 (-0.42%)

VIAB

Viacom

$43.99

-0.17 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MNTA

Momenta

, PFE

Pfizer

18:03
02/17/17
02/17
18:03
02/17/17
18:03
Hot Stocks
Momenta: Sandoz partner Pfizer receives FDA warning letter »

Momenta Pharmaceuticals…

MNTA

Momenta

PFE

Pfizer

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

CI

Cigna

$143.56

-1.77 (-1.22%)

, ANTM

Anthem

$160.25

-3.52 (-2.15%)

17:53
02/17/17
02/17
17:53
02/17/17
17:53
Periodicals
Cigna claims Anthem attempted to harm its business, Bloomberg says »

Cigna (CI) has accused…

CI

Cigna

$143.56

-1.77 (-1.22%)

ANTM

Anthem

$160.25

-3.52 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCMP

Sucampo

$11.80

0.05 (0.43%)

, NILE

Blue Nile

17:50
02/17/17
02/17
17:50
02/17/17
17:50
Hot Stocks
Sucampo to replace Blue Nile in the S&P 600 as of February 23 open »

Sucampo Pharmaceuticals…

SCMP

Sucampo

$11.80

0.05 (0.43%)

NILE

Blue Nile

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

VRML

Vermillion

$1.75

0.08 (4.79%)

17:39
02/17/17
02/17
17:39
02/17/17
17:39
Hot Stocks
Jack Schuler raises stake in Vermillion to 19.6% »

As of the date hereof,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITO

SITO Mobile

$2.29

0.08 (3.62%)

17:34
02/17/17
02/17
17:34
02/17/17
17:34
Hot Stocks
SITO Mobile announces Jerry Hug resigned as CEO, names O'Connell interim »

Effective February 1,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 29

    Mar

CEMI

Chembio Diagnostics

$6.05

0.05 (0.83%)

17:32
02/17/17
02/17
17:32
02/17/17
17:32
Hot Stocks
Breaking Hot Stocks news story on Chembio Diagnostics »

ARS Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

17:31
02/17/17
02/17
17:31
02/17/17
17:31
Hot Stocks
Broadwood raises stake in BioTime to 24.5% »

Broadwood Partners,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

AHP

Ashford Hospitality Prime

$13.39

0.19 (1.44%)

17:30
02/17/17
02/17
17:30
02/17/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Ashford Hospitality Prime »

Sessa Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

HIIQ

Health Insurance Innovations

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Patrick McNamee reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HAR

Harman

$111.01

0.03 (0.03%)

, SSNLF

Samsung

17:28
02/17/17
02/17
17:28
02/17/17
17:28
Hot Stocks
Harman holders vote to approve Samsung deal »

According to a regulatory…

HAR

Harman

$111.01

0.03 (0.03%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

TST

TheStreet

$0.81

0.01 (1.25%)

17:21
02/17/17
02/17
17:21
02/17/17
17:21
Hot Stocks
Breaking Hot Stocks news story on TheStreet »

Raging Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$10.10

-0.65 (-6.05%)

17:17
02/17/17
02/17
17:17
02/17/17
17:17
Hot Stocks
Carl Westcott raises stake in Comstock Resources to 8.67% from 7.13% »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.